Clinical Trial Update: A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism [Phase 2]

View source ↗

Summary

A completed Phase 2A dose-ranging study evaluated the pharmacokinetics and dosing of the oral vitamin D compound DP001 in secondary hyperparathyroidism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• DP001

Snippet

Sponsor: Deltanoid Pharmaceuticals | Conditions: Secondary Hyperparathyroidism | Phase 2 | Status: COMPLETED